Related Experiment Videos

Wall passivation for unstable angina

M Lettino1, F Dailey-Sterling, L Badimon

  • 1Cardiovascular Biology Research Laboratories, Mount Sinai School of Medicine, New York, NY 10029, USA.

Seminars in Interventional Cardiology : SIIC
|March 1, 1996
PubMed

Insights

Platelet aggregation in coronary arteries drives arterial thrombosis and ischemia in unstable angina. Novel anti-platelet therapies, including direct thrombin inhibitors and glycoprotein IIb/IIIa antagonists, offer improved control of vascular occlusion.

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Pharmacology

Background:

  • Atherosclerotic plaque disruption is key to arterial thrombosis and ischemia.
  • Platelets are central to unstable angina pathogenesis, causing obstruction and thrombus extension.
  • Vascular occlusion is the primary target in unstable angina treatment.

Purpose of the Study:

  • To summarize the role of the vessel wall and platelets in arterial thrombosis.
  • To describe pharmacological approaches for platelet passivation in unstable angina.

Main Methods:

  • Review of current literature on arterial thrombosis and unstable angina.
  • Analysis of the interaction between the vessel wall and platelets.
  • Evaluation of existing and novel pharmacological agents for passivation.

Main Results:

  • Platelet aggregation can lead to mechanical obstruction and fibrin deposition.
  • Direct thrombin inhibitors and glycoprotein IIb/IIIa receptor antagonists show promise for passivation.
  • Understanding vessel wall-platelet interactions is crucial for therapeutic development.

Conclusions:

  • Effective control of unstable angina requires managing the acute disease process.
  • Novel anti-platelet agents may offer superior passivation compared to current therapies.
  • Targeting platelet activity is essential for preventing vascular occlusion in unstable angina.

Related Concept Videos